MedTrace Logo

Low Molecular Weight Heparin in Pregnancies With Unexplained Stillbirths

NCT03601338 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2018-12-10

No results posted yet for this study

Summary

Bemiparin for pregnant women with abnormal umbilical artery Doppler ultrasound

Conditions

  • Unexplained Stillbirth

Interventions

DRUG

Bemiparin

second generation low molecular weight Heparin

OTHER

multivitamins and routine antenatal follow up

multivitamins and routine antenatal follow up

Sponsors & Collaborators

  • Hawler Medical University

    lead OTHER

Principal Investigators

  • shahla k. Alalaf, M.D · Hawler Medical University, college of Medicine, department of Obstetrics and Gynecology

  • Ariana K. Jawad, CABOG · Kurdistan Board for Medical Specialist

  • Mahabad S. Ali, Diploma · Maternity Teaching Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-01
Primary Completion
2018-12-01
Completion
2018-12-06

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03601338 on ClinicalTrials.gov